Kyorin Pharmaceutical Co., Ltd. Licenses Immunosuppressant Drug To Novartis Corporation

TOKYO, Feb 16 (Reuters) - Japan's Kyorin Pharmaceutical Co. (4560.T: Quote, Profile, Research) said on Thursday it had granted a global license to Novartis AG (NOVN.VX: Quote, Profile, Research) to develop and market its immunosuppressant drug KRP-203, in an effort to speed up the launch of the drug.

Back to news